Transparent Biosimilar Labeling

Physicians need clear data to safely prescribe biosimilar medications.

Which Patients are Sick Enough for a Hepatitis C Cure?

Under many health plans, only the sickest can receive the cure they need.

Informing Physicians About Biosimilar Substitution

It’s a small price to pay for patient safety.

When Cancer Cost-Sharing Turns Toxic

Are insurers cost-shifting policies pricing cancer patients out of care?

The Path to a Hepatitis C Cure

Breakthrough therapies offer millions of Americans with hepatitis the long-awaited chance for a cure. But complex prior authorization requirements make accessing these cures difficult –

Read More

Which Infants are More Vulnerable to Respiratory Syncytial Virus

Lengthy Prior Authorization Processes

Lengthy prior authorization processes delay patient access to vital medications.

Clinical Trials Participation

The difference between a long-shot and a moon-shot.

Abuse-Deterrent Pain Medications

Without Access, Abuse-Deterrent Pain Medications Can’t Help the Patients Who Need Them

Access to Balanced Pain Management

Safer options for treating surgical pain.

Back to Top